Asset Details
Do you wish to reserve the book?
ALK阳性非小细胞肺癌脑转移患者的治疗
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ALK阳性非小细胞肺癌脑转移患者的治疗
Do you wish to request the book?
ALK阳性非小细胞肺癌脑转移患者的治疗
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ALK阳性非小细胞肺癌脑转移患者的治疗
2016
Overview
背景与目的间变性淋巴瘤激酶（anaplastic lymphoma kinase,ALK）阳性非小细胞肺癌（non-small cell lung cancer,NSCLC）是肺癌的一个重要亚型。ALK阳性NSCLC脑转移患者的治疗尚无标准模式。方法本研究对我院2013年3月-2016年3月期间确诊的ALK阳性NSCLC脑转移患者的临床资料和治疗情况进行回顾性分析,探讨不同治疗模式患者的转归。结果 84例晚期ALK阳性NSCLC患者中,22例初诊时有脑转移,剔除3例合并表皮生长因子受体（epidermal growth factor receptor,EGFR）双突变患者,共19例纳入分析。中位颅内疾病进展时间（progression-free survival,PFS）为12.0个月,一线脑部局部治疗（P=0.021）及一线克唑替尼治疗（P=0.030）可延长PFS;一线克唑替尼联合脑部局部治疗的中位颅内PFS为27.0个月,而单纯克唑替尼治疗的PFS仅为4.2个月。结论一线克唑替尼联合脑部局部治疗有助于延长ALK阳性晚期NSCLC患者的颅内PFS,因例数少,尚有待大样本多中心前瞻性临床研究证实。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.